CIC (Cambridge Innovation Center)’s Post

🆕 IGTP joins the Advanced Therapies Network of Catalonia Yesterday, Biocat, BioRegion of Catalonia presented the Advanced Therapies Network, an initiative coordinated by the organisation to promote research and development of these drugs, seeking to generate an economic and social impact in Catalonia. Its aim is to get these therapies to patients faster and project the BioRegion of Catalonia as a global benchmark hub in advanced therapies. The event brought together more than a hundred representatives from various advanced therapies stakeholders in Catalonia: startups and scaleups, production centers, investment funds, hospitals, universities and research centers, companies and the Healthcare System. A total of 45 companies and organisations have already joined the Network, including Germans Trias i Pujol Research Institute (IGTP). Learn more: https://lnkd.in/ddNjZpt8 Som ICERCA - Centres de Recerca de Catalunya Centre of excellence by Instituto de Salud Carlos III

"A lot has changed in the world of clinical research in the last year. Decentralized clinical trials are now much more a part and parcel of study protocols whether it is eConsent, ePRO, eCOA, Home Health Nursing, use of sensors/wearables or direct to patient shipment of medicinal products. In May of 2023 the draft ICH E6(R3) was released which is a major overhaul of the GCP guidelines since E6(R2). The conference provided a platform for all these major events in the clinical research ecosystem to be discussed, debated along with the best approaches for implementation in the South East Asian environment.” Dr. Sanish Davis MD, DM,FCP, President, Indian Society for Clinical Research #ISCR Further Read: https://lnkd.in/dj39QEuS

📢 Today’s National Biotech and Medtech Development and Commercialisation Summit 2024 in Canberra brings together more than 100 of Australia’s leading industry figures, policy experts, and innovators to shape the future of the nation’s biotech and medtech sectors with a unified voice. AusBiotech CEO, Rebekah Cassidy, said the Summit comes at pivotal time for Australian life sciences companies including innovators, manufacturers and service providers. “The factors influencing life sciences investment and growth are changing rapidly, which is why it’s crucial that AusBiotech leverage its national convening power to elevate the sector’s voice and lead evidenced-based policy discussions. Now is the time for a unified strategy and roadmap focused on enhancing industry’s development and commercialisation capabilities to bring more life changing medical innovations to market.” MTPConnect CEO Stuart Dignam says nurturing a culture of innovation and focus on commercialisation can make all the difference. “We need a coordinated strategy for backing life sciences innovation and supporting startups and SMEs through the difficult early years of innovation so we capture more opportunities to develop and commercialise sovereign medical products that create jobs, exports and health improvements.” Through this Summit, both organisations hope to provide a clear roadmap to government and industry stakeholders that aligns our policies, funding, and capabilities to accelerate the commercialisation of Australian innovations and position Australia as a global leader. Read more about the Summit.... Hon. Jaala Pulford, James Campbell, Karyn McIntosh, Rosanne Hyland, Lisa Dubé, Amelia Vom, Duncan Macinnis, Erin McAllum, Emma Boscheinen, Caroline Duell

From Japan to Denmark: Medical Incubator Japan K.K. invests in biotech company Hoba Therapeutics! 🇯🇵➡️🇩🇰   “It’s a great honour for us to take a co-lead position in this round. I firmly believe that Hoba Therapeutics’ programs will yield significant positive impacts on pain management and related therapies. This investment in an outstanding Danish company not only signifies our support, but also paves the way for future investments from Japan into Danish and other European biotech companies,” says Kenji Harada, Investment Officer at Medical Incubator Japan   This significant investment underscores Denmark's position as a leading innovation hub in the life science sector. Medical Incubator Japan's decision to invest in Hoba Therapeutics highlights Denmark's attractive business environment, strong government support, and thriving life science ecosystem.   Denmark's reputation as a global leader in life sciences, coupled with its robust research infrastructure and strategic location in Europe, makes it an ideal destination for international investors seeking opportunities in the biotech industry.   📰 Read more about why Medical Incubator Japan chose Danish biotech company, Hoba Therapeutics: https://lnkd.in/eKZgZZnj 🤙 Want to join or invest in the Danish life science industry? Please reach out to our experts here: Rumi Iida or Tine Hartmann Nielsen.   🔔 Don't miss out on the latest developments in the Danish life science sector! Follow Invest in Denmark for more updates and opportunities.   #InvestInDenmark #LifeSciences #Biotech #InnovationHub #InvestmentOpportunities

Learn about the growth issues that lie ahead for the Aus biotech sector with this new discussion paper by AusBiotech and MTPConnect.

[Taiwan’s Biomedical Industry Investment Directions and Development Trends] In 2024, Taiwan’s biomedical industry has entered a new wave of investment, with fundraising reaching record highs. The industry shows three key trends: 1️⃣ M&A has become a primary growth driver, 2️⃣ Leading new drug companies are seeing significant revenue growth, reaching nearly NT$1 billion in a single month, and 3️⃣ Internal spin-offs and repositioning are revitalizing established companies. Looking ahead, the industry will focus on innovative drugs, weight management and medical aesthetics, and chain-based smart healthcare services, uncovering numerous potential business opportunities. Key Investment Opportunities in Biomedical Industry: 🔹Innovative Drugs: Companies developing licensed products that address critical clinical needs will lead the market. 🔹Weight Management and Medical Aesthetics: With shifts in lifestyle and health awareness, this sector is rich in growth potential. 🔹Medical Technology and Chain-Based Healthcare Services: From NGS companion diagnostics and IVF reproductive medicine to AI applications in healthcare, these innovations boost efficiency and create opportunities for scalable, chain-based health services. As value-added investors, the CDIB BioScience Fund and BioScience II Fund actively support the growth of domestic biotech companies, often taking the lead investor role. Managing over NT$10 billion and investing in nearly 50 biotech firms, CDIB has built a complete ecosystem in partnership with domestic biomedical organizations, integrating capital, technology, and resources. Under the government’s “Five Key Trusted Industries” initiative, the recent approval of the NT$10 billion Smart Healthcare Fund is expected to further support the biomedical industry’s path toward a trillion-dollar market. With the rise of the aging society, CDIB BioScience Fund is expanding into the senior economy, leveraging AI technology. As the biomedical industry continues to advance across fields, we look forward to supporting more collaborations that drive the industry into a new golden era. #BiomedInvestment #InnovativeDrugs #WeightManagement #MedicalAesthetics #SmartHealthcare #ChainBasedHealthServices #SeniorEconomy #AI

The NIHR Invention for Innovation (i4i) Programme is delighted to launch its 28th round of i4i Product Development Awards (PDA) to support translational research and development of medical devices, in vitro diagnostics and high-impact patient-focused digital health technologies for ultimate NHS use. The research proposals may address any disease or health area, provided there is a clear unmet clinical need. There is no upper funding limit for Product Development Awards, but costs must be fully justified. The project can be led by small-to-medium-sized enterprises (SME), NHS providers or higher education institutions (HEIs) and must be collaborative between any two of the eligible types of organisation. The project can last a minimum of 24 months and a maximum of 36 months. i4i PDA Award 28 launched on 10th April 2024. https://lnkd.in/gNUpj6u

📢 NEWS: Today AusBiotech and MTPConnect have released a discussion paper on critical life science growth issues ahead of our upcoming National Biotech and Medtech Development and Commercialisation Summit, on 19 November 2024 in Canberra.   Australia's life sciences sector is an essential part of Australia’s economy, supporting high-paying and skilled jobs, manufacturing exports, and underpinning the health and wellbeing of Australians. It is rightly recognised by the Australian Government as a critical sector that is essential for Australia’s future. Yet while we are in the top ten globally for research, we slip down to 30th for the translation and commercialisation of that research. The upcoming Summit will see AusBiotech and MTPConnect gather some of the country’s most senior leaders from a cross-section of the biotech and medtech sector to tackle these issues.    The joint discussion paper launched today unpacks Australian and global policy contexts, stubborn industry challenges, and barriers to achieving robust “Development and Commercialisation” outcomes. MTPConnect CEO Stuart Dignam said the discussion paper and 19 November Summit aim to harness industry insights and create a united voice to government ahead of the 2025 election. “Medical products are one of Australia’s most significant value-add exports, but gaps in biomedical and medical technology product development limit our ability to fully realise the commercial potential of our innovation prowess,” Mr Dignam said. Add your voice to the discussion The Summit is one part of the conversation, and your insights are crucial to ensuring the discussions and any outputs reflect the diverse perspectives of the industry. If you aren’t attending the Summit, we invite you to complete the survey to share your views. Check out the discussion paper and survey below: https://lnkd.in/gmAjHbFp Stuart Dignam, Hon. Jaala Pulford, Rebekah Cassidy, Erin McAllum, Duncan Macinnis, Lisa Dubé, Amelia Vom, Andrew Bowskill, Tracey Wilkinson, Dana Bell

Medical device trials are on the rise in Latin America, with a jump from 40 trials in 2017 to 67 in 2020. This growth underscores the region's appeal, boosted by diverse populations and strong health relationships. "How Medtech Companies Are Unlocking The Potential Of Latin America In Clinical Research" explores how Colombia is streamlining trial approval processes and how bioaccess™, a key player in the space, is supporting US Medtech startups to navigate these opportunities effectively. Learn more about this exciting trend: https://bit.ly/3YazOFX 🩺🌎 #MedTech #ClinicalTrials #LatinAmerica